SEC Comment Letter 0000000000-24-012639 to Arbutus Biopharma Corp (ABUS) (CIK 0001447028) (ABUS)
Arbutus Biopharma Corp (ABUS) (CIK 0001447028)
Date: Nov. 14, 2024 · CIK: 0001447028 · Accession: 0000000000-24-012639
AI Filing Summary & Sentiment
File numbers found in text: 333-283038
Letter
November 14, 2024 Michael McElhaugh Chief Executive Officer Arbutus Biopharma Corporation 701 Veterans Circle Warminster, PA 18974 Re:Arbutus Biopharma Corporation Registration Statement on Form S-3 Filed November 6, 2024 File No. 333-283038 Dear Michael McElhaugh: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Tyler Howes at 202-551-3370 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc:Stephen Nicolai, Esq.
Show Raw Text
November 14, 2024
Michael McElhaugh
Chief Executive Officer
Arbutus Biopharma Corporation
701 Veterans Circle
Warminster, PA 18974
Re:Arbutus Biopharma Corporation
Registration Statement on Form S-3
Filed November 6, 2024
File No. 333-283038
Dear Michael McElhaugh:
This is to advise you that we have not reviewed and will not review your registration
statement.
Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you
that the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Tyler Howes at 202-551-3370 with any questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc:Stephen Nicolai, Esq.